Genpact Announces Renewed Partnership with Ferring Pharmaceuticals
Genpact (NYSE: G) has announced the extension of its partnership with Ferring Pharmaceuticals through a renewed multi-year agreement. The collaboration focuses on transforming Ferring's finance, accounting, and procurement operations using advanced technologies, including AI. Genpact will continue to streamline workflows, optimize resource allocation, and enhance financial transactions by automating key processes through partnerships with Xelix and Blackline. The partnership, which already encompasses over 40 digital transformation projects, aims to deliver operational savings and enable Ferring to respond quickly to market demands.
Genpact (NYSE: G) ha annunciato l'estensione della sua partnership con Ferring Pharmaceuticals attraverso un rinnovato accordo pluriennale. La collaborazione si concentra sulla trasformazione delle operazioni di finanza, contabilità e approvvigionamento di Ferring utilizzando tecnologie avanzate, inclusa l'AI. Genpact continuerà a snellire i flussi di lavoro, ottimizzare l'allocazione delle risorse e migliorare le transazioni finanziarie automatizzando processi chiave attraverso le partnership con Xelix e Blackline. La partnership, che già comprende oltre 40 progetti di trasformazione digitale, mira a garantire risparmi operativi e a consentire a Ferring di rispondere rapidamente alle domande del mercato.
Genpact (NYSE: G) ha anunciado la extensión de su asociación con Ferring Pharmaceuticals a través de un renovado acuerdo multianual. La colaboración se centra en transformar las operaciones de finanzas, contabilidad y adquisiciones de Ferring utilizando tecnologías avanzadas, incluida la IA. Genpact seguirá optimizando los flujos de trabajo, mejorando la asignación de recursos y reforzando las transacciones financieras mediante la automatización de procesos clave a través de asociaciones con Xelix y Blackline. La asociación, que ya abarca más de 40 proyectos de transformación digital, tiene como objetivo proporcionar ahorros operativos y permitir que Ferring responda rápidamente a las demandas del mercado.
Genpact (NYSE: G)는 Ferring Pharmaceuticals와의 파트너십을 갱신된 다년 계약을 통해 연장했다고 발표했습니다. 이번 협력은 Ferring의 재무, 회계 및 조달 작업을 AI를 비롯한 첨단 기술을 사용하여 혁신하는 데 집중하고 있습니다. Genpact는 워크플로우를 효율화하고, 자원 배분을 최적화하며, Xelix 및 Blackline과의 파트너십을 통해 주요 프로세스를 자동화하여 금융 거래를 강화할 것입니다. 이미 40개 이상의 디지털 전환 프로젝트를 포함하고 있는 이 파트너십은 운영 비용 절감과 Ferring이 빠르게 시장 수요에 대응할 수 있도록 하는 것을 목표로 하고 있습니다.
Genpact (NYSE: G) a annoncé la prolongation de son partenariat avec Ferring Pharmaceuticals par le biais d'un nouvel accord pluriannuel. Cette collaboration est axée sur la transformation des opérations financières, comptables et d'approvisionnement de Ferring en utilisant des technologies avancées, y compris l'IA. Genpact continuera à rationaliser les flux de travail, à optimiser l'allocation des ressources et à améliorer les transactions financières en automatisant des processus clés grâce à des partenariats avec Xelix et Blackline. Ce partenariat, qui englobe déjà plus de 40 projets de transformation numérique, vise à générer des économies opérationnelles et à permettre à Ferring de répondre rapidement aux demandes du marché.
Genpact (NYSE: G) hat die Verlängerung seiner Partnerschaft mit Ferring Pharmaceuticals durch eine erneuerte mehrjährige Vereinbarung bekannt gegeben. Die Zusammenarbeit konzentriert sich auf die Transformation von Fertigung, Buchhaltung und Beschaffung bei Ferring unter Einsatz fortschrittlicher Technologien, einschließlich KI. Genpact wird weiterhin Arbeitsabläufe optimieren, Ressourcenallokation verbessern und Finanztransaktionen durch die Automatisierung zentraler Prozesse in Zusammenarbeit mit Xelix und Blackline fördern. Die Partnerschaft, die bereits über 40 digitale Transformationsprojekte umfasst, zielt darauf ab, Betriebseinsparungen zu erzielen und Ferring zu ermöglichen, schnell auf Marktanforderungen zu reagieren.
- Multi-year contract renewal with major pharmaceutical client
- Partnership expansion across 40+ digital transformation projects
- Implementation of automation and AI solutions promising operational cost savings
- None.
Insights
The renewed multi-year partnership between Genpact and Ferring Pharmaceuticals represents a significant operational enhancement initiative, though financial terms remain undisclosed. The collaboration focuses on modernizing Ferring's finance, accounting and procurement operations through AI integration and partnerships with technology providers like Xelix and Blackline.
The implementation of automated invoice management and procurement workflows, combined with enhanced data analytics capabilities, should drive operational cost savings and improve efficiency. For Genpact, this partnership renewal validates their expertise in digital transformation and strengthens their position in the healthcare and life sciences sector. However, without specific financial details or contract value, the immediate revenue impact remains unclear.
Renewed multi-year partnership to support Ferring Pharmaceuticals' operations in response to rapid business growth
"To drive growth in a complex and competitive environment, pharmaceutical companies need modern, scalable and efficient solutions," said Sanjiv Tandon, Global Head of Life Sciences and Healthcare, Genpact. "Our ongoing partnership with Ferring Pharmaceuticals leverages our industry expertise and a shared vision to harness advanced technologies, setting a new standard for innovation and enabling Ferring to meet evolving demands with speed and accuracy."
Under the agreement, Genpact will continue to streamline workflows, optimize resource allocation, and improve the accuracy and speed of financial transactions. In collaboration with technology partners like Xelix and Blackline, Genpact will automate key processes, such as invoice management and procurement workflows, while establishing robust data analytics capabilities for real-time financial insights. These enhancements aim to deliver significant operational savings and enable Ferring to adapt swiftly to evolving customer and patient needs.
"Our partnership with Genpact spans over 40 digital transformation projects, with a strong focus on AI applications," said Dominic Moorhead, Chief Financial Officer, Ferring Pharmaceuticals. "By standardizing processes and leveraging advanced technologies, like AI, we're enhancing accuracy, real-time insights, and overall efficiency to support our purpose of building families and helping people live better lives."
This collaboration underscores Ferring Pharmaceuticals' commitment to innovation, enabling the company to thrive and deliver its range of innovative treatments to change the lives of people and families around the world.
To learn more about Genpact's solutions and services for Healthcare and Life Sciences industries, click here.
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook.
MEDIA CONTACT:
Sue Martenson
Genpact Media Relations
+1 978-905-9582
susan.martenson@genpact.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-announces-renewed-partnership-with-ferring-pharmaceuticals-302312504.html
SOURCE Genpact Ltd.
FAQ
What is the new partnership between Genpact (NYSE: G) and Ferring Pharmaceuticals?
How many digital transformation projects has Genpact (NYSE: G) implemented with Ferring?
What technologies will Genpact (NYSE: G) use in its partnership with Ferring?
